Patents by Inventor Toshimitsu Matsui

Toshimitsu Matsui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7427671
    Abstract: A DNA sequence which encodes a human type ? platelet derived growth factor receptor protein which preferentially binds to the AA homodimer and AB heterodimer forms of platelet derived growth factor and also binds the BB homodimer at high affinity, is described. Substantially pure human a platelet derived growth factor receptor protein and methods for recombinantly producing human ? platelet derived growth factor receptor protein are also described.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: September 23, 2008
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Patent number: 7252929
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: August 7, 2007
    Assignee: United States of America, as represented by the Secretary, Dept of Health & Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Publication number: 20050112582
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 26, 2005
    Inventors: Toshimitsu Matsui, Stuart Aaronson, Jacalyn Pierce
  • Patent number: 6660488
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: December 9, 2003
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Publication number: 20020055129
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Application
    Filed: January 25, 2001
    Publication date: May 9, 2002
    Applicant: The Government of The United States of America, as
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Patent number: 6228600
    Abstract: Recombinant DNA technology was used to clone encoding nucleic acids for the human alpha platelet-derived growth factor receptor (PDGF-R type alpha). Peptides corresponding to the predicted sequence of this type and of the PDGF-R type beta were used to elicit antibodies specific for either type of the PDGF-R. Immunoassays are described for determining the level of PDGF-R type alpha in biological samples with the PDGF-R type alpha-specific antibodies.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 8, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Patent number: 5965359
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 12, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce